The timing of the exposure during pregnancy made a big difference in the level of risk associated with developing an allergic condition.

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.

MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.

Neurocrine’s Crenessity is an oral corticotropin-releasing factor type 1 receptor antagonist. Credit: Piotr Swat/Shutterstock. Neurocrine Biosciences has presented new one-year data from its Phase III ...

Amylyx has presented new exploratory analyses from the Phase II PREVENT and Phase IIb trials of avexitide for PBH treatment.

Verastem has reported primary analysis data from the Phase II RAMP 201 trial, where the avutometinib combination showed an ORR of 31% ...

Takeda’s oral narcolepsy drug, oveporexton, has met the primary and secondary endpoints in two Phase III trials. The FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials both met all their ...

Crinetics Pharmaceuticals has revealed new data from its clinical development programme for Palsonify, an oral treatment for acromegaly.

A strategic framework has been devised with nine priority actions to enhance quality, accessibility, innovation and sustainability in trials.

Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have showed NeoVaxMI's improved immune response in melanoma patients.

According to the World Health Organization, autism spectrum disorder (ASD) affects approximately 10% of children globally. ASD is theorised to be caused by a combination of genetic and environmental ...

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.